From Bench Science to Boardroom Strategy: How Dr. Laurie Myers Shapes Ethical Pharma Innovation
What happens when a lifelong scientist steps into the driver’s seat of commercialization — and discovers the business decisions behind life-changing medicines?
Dr. Laurie Myers, CEO of Hallett Davis Strategic Group, has lived that journey.
From toxicology labs to executive leadership at global pharmaceutical companies, she has worked at the intersection of science, ethics, and business strategy for more than two decades.
On Industry Ignited, she shares how the next era of pharma demands not just innovation —
but accountability, humility, and courage to keep patients at the center of the purpose.
A Leap From Science into Strategy — Fueled by Someone Seeing Her Potential
Laurie never planned to leave the lab.
She earned a Bachelors, Masters, PhD, and two post-docs in science before corporate restructuring forced a fork in the road. A senior leader who admired her reliability and discipline asked her to move into marketing — a world she had never once considered.
And she jumped.
Across the country, into a new discipline, with a one-year safety net…
that she never needed.
“I never left science.
My science walks with me every day as a businesswoman.”
That bold decision changed the trajectory of her entire career.
Inside Big Pharma — Where Innovation, Leadership & Resources Converge
Working at Novartis and other major organizations gave Laurie visibility into what truly drives pharmaceutical progress:
✔ Investment is the lifeblood of innovation
✔ Cross-functional mentorship accelerates careers
✔ Small biotech thinking inside big organizations births breakthroughs
She saw what most don’t: large companies can incubate nimble innovation, acting like startups with the scale to commercialize.
It was in this environment Laurie learned resilience — and how organizational structure can either fuel or stall scientific discovery.
The Skill That Became Her Superpower: Translating Science Into Business
In her first marketing meeting, Laurie admits:
she didn’t understand a single word.
So she learned.
Regulations on weekends.
An MBA while working full-time.
The language of finance, positioning, and competitive strategy.
That transformation gave her a unique ability — to be a translator:
🔹 She can speak data and clinical endpoints with researchers
🔹 She can speak market needs and growth with commercial teams
🔹 She can guide product decisions that serve the patient and the business
“There’s a rhythm in marketing, just like there’s a rhythm in science.”
Today, that translation skill is mission-critical — especially in an era where AI is changing everything.
AI, Innovation & Ethics — The New Crossroads of Pharma
Laurie has watched the industry move from pre-internet systems to AI-driven discovery and decision-making.
And she’s not watching from the sidelines — she’s deep in the learning:
🧠 MIT coursework
📚 Seminars on AI compliance
🌐 Studying ethical frameworks
Her biggest message?
AI isn’t coming.
It’s here.
And the industry must ensure:
-
Human oversight stays central
-
Truth sources are protected (NIH, peer-reviewed data, real clinical evidence)
-
AI systems don’t unintentionally perpetuate bias — especially when historical data excludes women and people of color
“We can’t fear AI —
but we must be intimate with it.”
Bringing Medicines to Market: It Starts With Listening
Across the hundreds of launches she has supported, Laurie says the secret isn’t a secret:
🩺 Listen to healthcare providers
📊 Listen to the marketplace data
Those closest to patients reveal what numbers alone cannot.
That dual listening — clinical + commercial — ensures medicines don’t just exist…
they reach and work for the people who need them.
Surviving Mergers & Reinvention — Choosing Not to Quit
Throughout her career, Laurie has lived the reality of pharma:
companies merge, structures shift, roles disappear.
Each transition expanded her network and leadership skills.
Some organizations worked.
One lasted only nine months — and leaving was still the right choice.
“You gain resilience.
You learn when to stay… and when not to.”
That experience eventually led her to start Hallett Davis Strategic Group — a consulting firm built on decades of wisdom in commercialization and ethical leadership.
And today, she’s relaunching it with purpose.
Fractional Leadership: Guiding Companies Through Change
As more pharma companies turn to experienced fractional executives, Laurie sees an advantage:
✔ Rapid leadership continuity
✔ Fresh perspective without long onboarding
✔ Empathy during restructuring and organizational uncertainty
Whether serving short-term or stepping into a full-time role, she believes fractional leaders can stabilize teams where trust is shaken.
Because leadership isn’t just direction —
it’s reassurance.
Championing Women in Pharma — Progress Made, More to Go
Laurie has watched the industry evolve from an era where:
❌ Most mothers didn’t work
❌ Women rarely held leadership seats
to a world where:
✔ More women rise into the C-suite
✔ Spouses share the load at home
✔ Careers and family no longer compete — they coexist
But the work isn’t finished.
Representation still needs to grow.
And confidence still needs nurturing — one opportunity at a time.
Purpose Is the Constant — Even When Everything Else Changes
Through science, business, parenting, divorce, promotions, restructures, consulting, and reinvention…
One truth has guided Laurie:
Never give up.
Stay in the game.
Say yes to the opportunity — even when it scares you.
Passion for science.
Passion for patients.
Passion for progress.
That’s the heart of her leadership — and the heart of pharma at its best.
🎧 Listen to Dr. Laurie Myers on Industry Ignited
Discover how ethical commercialization and bold curiosity are shaping the future of medicines.
👉 Tune in here: https://www.buzzsprout.com/2514972
Interested in being featured on the podcast?
Contact: podcast@industryignited.com
